Could Adding a TLR9 Agonist Improve Responses in Metastatic Melanoma?

The combination of pembrolizumab and a TLR9 agonist known as SD-101 showed promising activity in patients with unresectable or metastatic melanoma.

Source: CancerNetwork - September 5, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news